Shares of GT Biopharma Inc (OTCMKTS:GTBP) rose 23.1% on Monday . The stock traded as high as $0.16 and last traded at $0.16, approximately 313,738 shares changed hands during trading. An increase of 142% from the average daily volume of 129,852 shares. The stock had previously closed at $0.13.
The firm has a 50 day moving average price of $0.18 and a two-hundred day moving average price of $0.14.
GT Biopharma (OTCMKTS:GTBP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.02) earnings per share for the quarter.
GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology products based off its proprietary technology platforms. The company develops immuno-oncology product candidates, including OXS-1550, a bispecific scFv recombinant fusion protein-drug conjugate that targets cancer cells expressing the CD19 receptor or CD22 receptor, or both receptors; OXS-3550, a single-chain, tri-specific scFv recombinant fusion protein conjugate targeting CD33+ malignancies; OXS-C3550, a next-generation version of OXS-3550 containing a modified CD16 component; and OXS-1615, a single-chain fusion protein that targets epithelial tumors and CD133 positive solid tumors.
Read More: What is a recession?
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.